American Capital Advisory’s BioMarin Pharmaceuticals BMRN Stock Holding History

American Capital Advisory’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15K	Buy	20 +15	+300%	+$822	﹤0.01%	759
2026 Q1	$283	Buy	5 +4	+400%	+$233	﹤0.01%	977
2025 Q4	$60	Sell	1 -1	-50%	-$54	﹤0.01%	1049
2025 Q3	$109	Hold	2	–	–	﹤0.01%	953
2025 Q2	$110	Sell	2 -2	-50%	-$118	﹤0.01%	834
2025 Q1	$283	Buy	+4	New	+$269	﹤0.01%	634

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

American Capital Advisory's BMRN Position: Q2 2026 in Review

American Capital Advisory increased its BioMarin Pharmaceuticals (BMRN) stake by 300% in Q2 2026, buying an estimated $822 and bringing the position to 20 shares worth $1.15K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

American Capital Advisory first reported a position in BMRN in Q1 2025 and has held it in 6 quarters since. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

American Capital Advisory held 20 shares of BioMarin Pharmaceuticals worth $1.15K as of Q2 2026.
American Capital Advisory bought 15 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $822.
BioMarin Pharmaceuticals made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #759 holding.
American Capital Advisory first reported a position in BioMarin Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.